Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights (GlobeNewswire) - May 30, 2025 - "Q1 2025 FINANCIAL RESULTS:...The Company recognized $1.1 million in grant revenue in the first quarter of 2025 compared to $1.7 million in in the first quarter of 2024, which represents CPRIT's share of the costs incurred for our REYOBIQ platform advancement for the treatment of patients with LM."
Commercial • CNS Tumor
|